

Nadine Piorkowsky, ELPA for ANGELOS HATZAKIS

PROFESSOR OF EPIDEMIOLOGY & PREVENTIVE MEDICINE
DIRECTOR, DPT OF HYGIENE, EPIDEMIOLOGY & MEDICAL STATISTICS
ATHENS UNIVERSITY MEDICAL SCHOOL

Budapest 18-19. March 2010, VHPB Meeting


Summit Conference Hepatitis 2 and Hepatitis C Brussels, October 2010

- Viral hepatitis constitutes one of the most widespread and rapidly growing public health problems faced by developed and developing countries.
- Implications of Hepatitis B and C are still poorly understood at a political and a public level

Summit Conference Hepatitis 2 and Hepatitis C Brussels, October 2010

A. Conference on Hepatitis B and C focusing on engaging policy makers, stakeholders and key opinion leaders in EU who can affect policy change.

B. Fast track research and pooled analyses of existing data to support a comprehensive public health strategy for HBV/HCV in Europe.



CORE STEERING GROUP(1)

Co-Chairs

- Angelos Hatzakis Athens University Medical School
- Nadine Piorkowsky European Liver Patients Association (ELPA)
- Massimo Colombo University of Milan

Treasurer


Rafael Esteban - Vall d' Hebron University Hospital, Barcelona



CORE STEERING GROUP (2)

Members

- Manuel Carballo International Centre for Migration & Health
- Charles Gore World Hepatitis Alliance/ The Hepatitis C Trust
- Harry Janssen Erasmus University
- Michael Manns Hannover Medical School
- Patrick Marcellin University of Paris
- George Papatheodoridis Athens University
- Howard Thomas Imperial College, London
- Heiner Wedemeyer Hannover Medical School (EASL)
- Dominique Valla University of Paris VII, France (EASL)




ADVISORY BOARD

- European Centre for Disease Control & Prevention (ECDC) - (M. van de Laar)
- Viral Hepatitis Prevention Board (VHPB) (P. van Damme)
- WHO (invited)




ENDORSEMENT

- European Commission
- Belgian Government
- World Health Organisation (WHO)
- European Centre for Disease Control (ECDC)
- Viral Hepatitis Prevention Board (VHPB)
- European Association for the Study of the Liver (EASL)
- European Liver Patients Association (ELPA)



RESEARCH PRIORITIES

- Prevalence of HBV and HCV in Europe (EU 27) ECDC
- ❖ Burden of HBV and HCV disease in Europe (EU 27) ECDC
- Cost effectiveness of HBV and HCV screening
- Migration and HBV/HCV in Europe: Barriers to prevention and treatment
- Patient self-help in the EU Member States




DELIVERABLES

- Awareness and Prevention
- 2. Enhancing Surveillance for HBV and HCV by ECDC
- 3. Screening/case findings for HBV/HCV and Related Diseases where co-infection is common
- 4. Universal Access to Early Treatment in line with Evidence-Based Guidelines
- 5. Expansion of research resources under the 7th and 8th Research Framework Programmes of the EU




Awareness and Prevention (1)

- Public Awareness campaigns
- HBV vaccine
- Social integration of individuals infected with HBV and HCV
- Reassessment of HBV vaccination policies
- Immigrants
- Protection of IVDU and prisoners
- Health care workers and other occupationally exposed
- Blood donors



Awareness and Prevention (2)

- Pregnant women and newborns
- HIV infected persons
- Household contacts
- Persons with STD
- International travellers
- Hemodialysis patients
- Integration of prevention into existing public health frameworks



Enhancing Surveillance for HBV and HCV by ECDC

- Acceleration and maintenance of European-wide surveillances
- Mandatory notification of Chronic Disease.



Screening/Detection for HBV/HCV and Related Diseases where co-infection is common


- Indicator disease / risk factor screening
- Cost-effectiveness of screening
- Legal and ethical implication of screening
- Guidance on settings where HBV screening is offered
- Antenatal screening
- Availability of risk group screening, such as migrants or IDUs
- Blood donor screening
- Screening for Hepatocellular carcinoma
- Engagement of local community leaders to encourage screening



Universal Access to Early Treatment in line with Evidence-Based Guidelines

- Earlier use of effective treatment
- Universal and equal access to HBV/HCV therapy
- Acceptance of and adherence to European treatment protocols

Expansion of research resources under the 7th and 8th Research Framework Programmes of the EU



www.hepsummit2010.org

Thank you!